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1. Introduction
  West Nile virus (WNV), a pathogenic arbovirus belongs 
to genus flavivirus, family Flaviviridae. Its natural 
transmission cycle involves reservoir hosts viz. wild and 
domestic birds. Mosquitoes, generally Culex species act 
as principal vectors, humans are dead end hosts[1,2].  Most 
of the human WNV infections remain subclinical. Febrile 
illness and neuroinvasive disease develop in ~20% and 
<1% of the infected patients respectively[3]. Initially, the 
virus was distributed in Africa, Asia and Europe where it 
caused infrequent and unpredictable epidemics of mild 
systemic disease[4]. However, the virus has spread rapidly 
to new regions like Romania (1996) and the United States 
(1999) and recently in Greece and Italy (2010) resulting in 
hundreds of neurological and fatal cases worldwide[4-6]. In 
India, antibodies against WNV were first detected in human 
sera from Bombay (1952)[7]. Since then, febrile illness in 
epidemic form and clinically overt encephalitis cases have 
been observed from southern, central and western India[8]. 
During 2006, WNV was detected in Assam as another 
etiological agent causing acute encephalitis syndrome in 
addition to the endemic Japanese encephalitis virus (JEV)[9]. 
Control of WNV is difficult due to availability of abundant 
breeding habitats of potential vectors and role of frequently 
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visiting migratory birds which act as reservoir hosts in the 
virus transmission cycle. Evidence of nonvector transmission 
like intrauterine and mother-to-child transmission of WNV 
via breast milk further suggest a complex epidemiology of 
the disease[10]. Therefore, the development of a safe and 
effective vaccine attains an urgent priority. 
  Currently, there are five inactivated and chimeric vaccines 
licensed for veterinary use[11]. However, no human vaccine is 
available though several candidate vaccines are in clinical 
trial. A Chimeric vaccine Chimerivax-WN02 in phase 栻 
clinical trial is found to be safe and highly immunogenic 
in adults and elderly persons[12]. One important factor to 
consider when evaluating flavivirus vaccine candidates is 
the possibility of cross protection due to similarities among 
viral epitopes. Studies in experimentally infected bonnet 
macaques have shown that inoculation with inactivated WNV 
results in limited protection against a JEV challenge, while 
inactivated JEV immunization offers full protection against 
a WNV challenge[13]. A study in mice showed that formalin 
inactivated West Nile (WN) vaccine candidate viz. WN-VAX 
is a safe and effective vaccine that offered 100% protection 
against lethal WNV challenge[11]. Consequently, there is 
considerable concern and scientific interest regarding 
invasion of WNV into a JEV endemic region. In Assam, a 
JE endemic belt; subsequent invasion of WN in 2006 has 
led to newer public health concerns. It will be important to 
study the immune response of circulating WNV strain and 
to assess its cross protective role. WNV strains are classified 
into at least 8 putative genetic lineages[14], in which, all 
the Indian isolates from 1950s to 1980 fall under lineage V, 
with two exceptions; one from a human patient (1967) and 
another from a bat (1968)-both closely related to the lineage 
1 strain[15]. To our knowledge, no study has been undertaken 
to study the immune response and efficacy of WNV isolates 
from India.
  In the present study, a Baby Hamster kidney 21 (BHK-21) 
cell culture derived, formalin inactivated WNV isolated from 
human clinical sample in Assam during 2007 was assessed 
for its immunogenicity and efficacy. WNV was inactivated 
at different temperatures to screen the best condition for 
inactivation in terms of toxicity and antigenicity. It was 
further assessed for cross neutralization and immunogenic 
potential in augmenting humoral and cellular immune 
response in Swiss albino mice model.
2. Materials and methods
2.1. Virus
   A circulating strain of WNV: WNIRGC07, isolated in 2007 
from human acute encephalitis syndrome patient (GeneBank 
ID: HQ246154) from Assam, India, was used. Phylogenetic 
analysis placed it under lineage V (RMRC, Dibrugarh 
unpublished data). Four virus passages in infant Swiss albino 
mice and subsequently two passages in BHK-21 cell line 
were done to increase adaptability and virus titer. An Indian 
prototype strain of JEV, P20778 (Isolated in 1985, human 
brain: AF080251) was used to check for cross protection and 
an Indian WNV prototype strain G22886 (isolated in 1980, 
Culex vishnui: DQ256376) was used as control. Virus strains 
were obtained from the virus repository of National Institute 
of Virology, Pune, India. 
 
2.2. Cells and cell propagation
  BHK-21cell line was used to propagate the virus. The cell 
line was obtained from National Centre for Cell Science, 
Pune, India, and maintained in Eagles Minimal Essential 
Medium (EMEM, Sigma) supplemented with 10% heat 
inactivated fetal bovine serum, 7.5% sodium bicarbonate 
(Sigma) and 2 mM L-glutamine. 
2.3. Virus production
  BHK-21 cells were grown on Cytodex-1 microcarrier 
(Sigma) prepared according to manufacturer’s instructions in 
5 000 mL capacity bioreactor (Bioflow 110, New Brunswick 
Scientific). Cytodex-1 beads were suspended into 9暳10
3 
BHK-21 cells/mL culture medium at a concentration of 2 g/L.
Cells were then allowed to attach on microcarriers for 3 h at 
37 曟, with intermittent stirring. Volume of the media was 
made up to 3 000 mL. Bioreactor was then incubated at 37 曟 
under SPM and stirred at 40 rpm. After 4 d the confluent 
beads were infected with virus inoculums added at a 
multiplicity of infection of 0.1. It took 4 d for the cytopathic 
effect (CPE) to become pronounced and at this stage BHK-
21 cells were detached from the cytodex beads. The culture 
supernatant was harvested and virus titers were determined 
by CPE assay[16].
2.4. Formalin inactivation
  The virus infected culture supernatant was clarified by 
centrifugation at 10 000 rpm for 1 h at 4 曟. Formalin (37% 
formaldehyde, Merck) was diluted 1:40 in PBS (the final pH 
7.2-7.4) and was filtered through a 0.22 毺m nitrocellulose 
filter unit. A final concentration of 5 mM formaldehyde 
was added to the suspensions for inactivating the virus 
at 3 different temperatures viz. 22 曟, 4 曟 and room 
temperature for 10 d. The suspensions were centrifuged at 
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10 000 rpm for 1 h at 4 曟. The supernatant was treated with 
protamine sulphate (1 毺g/mL) and kept at 4 曟 for 30 min. 
The suspension was centrifuged at 5 000 rpm for 20 min. 
Inactivated virus preparations were tested for residual virus 
infectivity by intra-cerebral inoculation of neonatal mice 
and on to monolayer of BHK-21 cell line. 
  
2.5. Inactivated virus antigenicity
  The antigenicity of virus preparations were determined 
by indirect antigen capture ELISA by following standard 
method[17]. Nunc maxisorp microtitre plates were coated 
with 50 毺L/well of Flavivirus specific monoclonal antibody 
(HX-B) at a dilution of 1:50 in coating buffer. Biotinylated 
HX-B was used as detector antibody.
2.6. In vitro microcytotoxicity assay
   Cell toxicity assay of inactivated virus preparations 
were evaluated for cell cytotoxicity by using 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyl-tetrazolium Bromide 
(MTT) cell Proliferation kit (Roche) with slight modification. 
Briefly, 10 毺L of inactivated virus preparation was 
inoculated into a 96 well plate pre-seeded with 3.5暳10
5 
cells/mL. After the incubation period, the treated cells 
were evaluated for cell cytotoxicity by adding 10 毺L of 
MTT labeling reagent and incubated for 4 h in incubator. A 
total of 100 毺L of solubilization reagent (Roche) was added 
into the treated wells and left overnight in incubator. The 
percentage of cytotoxicity was calculated as [(A-B)/A暳100] 
where A and B are the absorbances of control and treated 
cells respectively[18]. 
2.7. Reverse transcriptase (RT)-PCR
  The viral RNA was extracted from 140 毺L of inactivated 
virus and an untreated WNV pool as a positive control 
using QIAamp viral RNA mini kit (Qiagen, Germany), 
according to manufacturer’s instruction. RT-PCR was done 
targeting the NS5 region of WNV using the primer sequence 
Forward 5’-GCTCCGCTGTCCCTGTGA-3’ and reverse 5’- 
CACTCTCCTCCTGCATGGATG-3’[19]. Briefly, two steps RT-
PCR was carried out; cDNA was prepared using MMLV 
reverse transcriptase enzyme. PCR was done with 25 毺L
reaction volume containing 12.5 毺L of Promega 2暳PCR 
master mix, 2 毺L of 10 毺m primers. The thermal profile 
was set at 94 曟 for 3 min, 35 cycles of 94 曟 for 30 sec, 59 曟 
for 1 min, 72 曟 for 1 min and final extension at 72 曟 for 5 min.
Amplified product was run in Bioanalyzer (Agilent) for 
screening of any WNV nucleic acid.
2.8. Animal immunization and virus challenge
2.8.1. Mice immunization
   For immunogen preparation and efficacy test, the best 
suitable inactivated virus preparation was mixed with equal 
volume of alhydrogel (2% alum, Sigma) and incubated at 
room temperature for 30 min and stored at 4 曟. A total of 
12 groups (n = 8 each) of 3 to 4 week old Swiss albino mice 
were immunized subcutaneously with 50 毺g of immunogen. 
Three groups were injected with PBS as control. Booster 
injections with same formulation were given on 14 and 28 d 
after first immunization. 
2.8.2. Efficacy tests
  One week after administration of the second booster 
dose, out of 12 groups immunized, 9 groups of mice were 
challenged with 7暳10
5 PFU/mL of WNIRGC07, WNV G22886 
strain and  JEV P20778 (3 groups each) and a control group 
challenged with PBS. All animal studies were conducted in 
accordance with experimental protocol approved by Animal 
Welfare and Animal Care Committee of RMRC, Dibrugarh.
2.9. Determination of humoral immune response
  Neutralizing antibodies against G22886, WNIRGC07 and 
P20778 virus strains were measured for the immune sera 
collected at 7 days post immunization by following standard 
method[15]. On day 7, post second booster administrations, 
2 groups of immunized mice and 1 control group were bled 
and serum was separated. They were pooled separately for 
immunized and control groups.
2.10. Assessment of cell mediated immune response
  On day 2 post second booster administrations, 1 group 
of immunized mice with and 1 control group were bled 
and serum was separated. They were pooled separately 
for immunized and control groups. Mice were sacrificed 
according to guidelines of laboratory animal handling. 
The cytokine profiling were done for interleukin-4 (IL-4), 
interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor 
necrosis factor (TNF-毩) by using BD biosciences ELISA kit 
as per manufacturer’s guidelines. 
2.11. Statistical analysis
  Ag capture ELISA data was determined as end point titer 
(log10) 暲SE against respective three temperature conditions. 
Survival rates of the immunized mice were expressed as the 
proportions of mice mortality at the end of the observation 
period. Chi-square test was used to determine significant 
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differences between the groups, P-value <0.05 was 
considered to be significant.
3. Results
3.1. Growth of WNV in BHK-21 cells using microcarriers
  BHK-21 cells grown on microcarrier (cytodex-1) beads 
were harvested 96 h post infection (pi) after appearance of a 
pronounced CPE. The virus titer on BHK-21 cell monolayer 
was found to be 107 TCID50 for the WNV cultured in BHK-21 
using micro carriers.
3.2. Inactivation of WNV
  WNV inactivation was confirmed after repeated passages 
into infant mice and BHK-21 cell monolayer. No mortality 
was observed in infant mice inoculated intracranially, 
whereas, infants inoculated with live virus died after 3-4 d 
of inoculation. CPE was not observed in cell monolayer in all 
the three conditions. Quantification of inactivated viral PCR 
amplicons in Bioanalyzer showed no sign of viral nucleic 
acid. ELISA generated absorbance in three conditions- 
22 曟, 4 曟 and RT are log10 (1.34暲0.02), log10 (1.25暲0.01) and 
log10 (1.22暲0.01). Antigenicity of the formalin inactivated 
virus preparation stored at 22 曟 was found to be higher with 
than those stored at 4 曟 and RT. 
3.3. Cell Toxicity evaluation by MTT assay 
  Cytotoxicity of inactivated WNV at three different storage 
temperature conditions was quantitatively determined by 
MTT assay. It was observed that the formalin treated virus 
stored at 4 曟 was most toxic (induced cell death in 21% 
of cells). However, the batch stored at RT was less toxic 
(inducing 6.78% cell death). The best result was shown by 
the batch stored at 22 曟 which produced only 2.99% cell 
toxicity. Thus, inactivation at 22 曟 was found to be the best 
suitable condition to study efficacy and immune response in 
mice and in in-vitro models.
3.4. Efficacy test
  Mice were observed for 4 weeks following the virus 
challenge; any symptom of sickness and total survival were 
recorded. The immunized mice offered complete protection 
against the WNV’s challenge [WNIRGC07-100% (P<0.05) and 
G22886-100% (P<0.05)] and partial protection [20.8% (P>0.05)] 
against JEV. Infant mice inoculated with JEV showed hind 
limb paralysis followed by death 8-10 d post-inoculation.
3.5. Assessment of humoral immune response  
  Anti-WNV neutralizing antibody of the immunized group 
of mice was assayed by a neutralization test. Neutralizing 
antibody titer of 1:625 was observed in the group 
administered with the second booster dose of the inactivated 
WNV antigen. This result suggest strong protective efficacy 
of the vaccine candidate in in vitro system. However, the 
post-immunized WNV specific mice sera showed minimal 
cross protective neutralizing antibodies against JEV with a 
titre of 1:25 (Figure 1).
3.6. Assessment of cellular immune response
  Further characterization of immune response in mice was 
carried out by investigating specific cytokine response 
to immunization. Compared to un-immunized mice sera, 
the immunized mice sera produced high level of pro-
inflammatory cytokines IL-6 and TNF-毩 and moderate 






Figure 1. Microseroneutralization test performed using WNV (G22886) 
and serial fivefold dilution of immunized mice sera (WNVIRGC 07, 
G22886, P20778) collected after 7 d of second booster dose. 
Table 1 
Concentrations of cytokines in immunized mice after 48 h of second 
booster dose with inactivated WNV (pg/mL).
Mice group Cytokine level
IL-10 IL-4 IL-6 TNF 毩
Control 5 8.5 9 8
Immunized 14 22 77 79
4. Discussion
  WNV invasion continues to expand its geographic 
distribution. This has a significant impact on both human 
and veterinary concerns. Currently, there is no approved 
commercially available vaccine for prevention of WNV 
infection in humans and case management is limited 
to symptomatic and supportive medication; therefore 
development of an effective vaccine against it attains a 
high priority. Immunogenicity and virulence of different 
strains should be characterized to assess their immunogenic 
properties. One of the main advantages of inactivated virus 
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vaccines is that they are safe and stable. They often do 
not require refrigeration which is an important selection 
criterion for its use in many developing countries. However, 
a disadvantage is the requirement of multiple booster doses 
to elicit and sustain an effective immune response. Further, 
in few cases the immune response may be imbalanced, 
leading to subsequent elicitation of the disease[20,21]. A 
recent study suggested a model for vaccination in JEV 
endemic areas where a single dose of WNV vaccination will 
be sufficient to elicit protection against JEV and WNV[22]. 
  In the present study, a BHK-21 adapted Indian isolate 
of locally circulating WNV was used to study immune 
response and efficacy for a probable vaccine candidate. 
The WHO recommends the use of BHK-21 cells in the 
quality testing of JE vaccines such as the virus-inactivation 
test and potency estimation[23]. To exploit the adherent 
properties of BHK-21 cells, we adopted the microcarrier 
technology in the controlled condition of bioreactor[24]. High 
WNV titer was achieved by using microcarrier beads. Out 
of three temperature conditions employed for storing the 
virus during the inactivation process, 22 曟 was found to 
be best suitable in account of higher antigenicity and less 
toxicity. Similar studies on JEV report inactivation at 22 曟 
are more immunogenic than that of inactivation at 4 曟
[25]. Although, the exact mechanism of RNA degradation 
through formalin inactivation is not known, it may be due 
to the fact that formaldehyde reacts with RNA forming an 
N-methylol (N-CH2OH) followed by an electrophilic attack 
to form a methylene bridge between amino groups resulting 
in cross-linkage between nucleic acids and proteins. 
This cross-linking inhibits reverse transcription of the 
extracted RNA and interferes in cDNA synthesis[26]. Similar 
complete inactivation of JEV and Chikungunya virus at 22 曟 
for 10 d with repeated filtration has been reported[27,28].
The immunogenic potential of BHK-21 adapted WNV 
Indian isolate was assessed through determination of 
humoral as well as cell-mediated immune response. 
The immune response of post-immunized mice sera 
was accomplished through determination of neutralizing 
antibodies. Studies carried out in humans and in animal 
model have indicated the importance of an effective 
humoral response in preventing flavivirus infection both in 
the periphery and within the central nervous system[29,30]. 
Successful vaccination against WNV requires induction of 
both neutralizing antibodies and cell-mediated immune 
responses. The role of cell mediated immunity in currently 
used vaccines (that have T-cell dependent antigens) 
is mainly by supporting antibody protection. T-cell 
independent antigens (eg., polysaccharides) do not stimulate 
cell mediated immunity and therefore do not produce 
durable immunity. Generally, killed vaccines elicit humoral 
immune response but poor inducer of cell-mediated 
immune responses (CMI). However, there is evidence of 
protective cell-mediated immune responses following 
immunization with killed viral vaccines against HIV, Sendai 
virus and chikungunya virus[28,31,32]. Since CMI is induced 
and regulated by cytokines, we studied the profile of four 
major cytokines. In present study, formalin inactivated 
WNV elicitated comparable amounts of TH1 response (IL-6 
and TNF-毩) and elicited minute level of TH2 response 
(IL-10 and IL-4). Activated TH1 cells produce a number 
of cytokines that defend against viruses either directly or 
indirectly.
  To test the efficacy of inactivated WNV against a lethal 
challenge, Swiss albino mice model was used. The 
efficacy experiment showed that immunized mice were 
100%protected against a lethal WNV G22886 challenge but 
they showed partial protection against JEV P20778. Our 
finding is in agreement with a study done on WN-VAX 
and JEV-VAX[22]. In our study higher levels of neutralizing 
antibodies against WNV and lower levels of cross-
neutralizing antibodies to JEV were found. There are studies 
which evaluated the efficacy of a formalin-inactivated WNV 
vaccine candidate of a lineage 1 New York strain (WNV-
NY99) and observed 100% protection in mice against WNV 
challenge[11]. In contrast we had performed our study in 
lineage V WNV strain circulating in India and observed full 
protection against WNV strain and partial protection against 
JEV in mice model which is important in geographic regions 
where WNV and JEV co-circulate. Moreover, we had studied 
TH1 response and TH2 response. 
  In conclusion, this study revealed that BHK-21 cells 
adapted microcarrier technology can support production of 
high titer of WNV. The formalin inactivated WNV elicited 
both humoral and cell-mediated immune response in 
mice. The protective efficacy was established through in 
vitro neutralizing antibody titer. These findings clearly 
suggest that Indian strain of WNV would be a promising and 
effective candidate for vaccine studies with high protective 
immune response. 
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